

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Interaction of $\beta$ -L-Adenosine-5'-triphosphate (L-ATP) with Human Deoxycytidine Kinase, Human DNA Primase and T4 DNA Ligase: Does the Chance Direct Enzymatic Enantioselectivity?

A. Verri<sup>a</sup>; A. Montecucco<sup>a</sup>; G. Gosselin<sup>b</sup>; V. Boudou<sup>b</sup>; S. Spadari<sup>a</sup>; J-L. Imbach<sup>b</sup>; F. Focher<sup>a</sup>

<sup>a</sup> IGBE, CNR, PAVIA, Italy <sup>b</sup> Laboratoire de Chimie Bioorganique UMR CNRS-USTL 5625, Université Montpellier II, Montpellier cedex 5, France

**To cite this Article** Verri, A. , Montecucco, A. , Gosselin, G. , Boudou, V. , Spadari, S. , Imbach, J-L. and Focher, F.(1999) 'Interaction of  $\beta$ -L-Adenosine-5'-triphosphate (L-ATP) with Human Deoxycytidine Kinase, Human DNA Primase and T4 DNA Ligase: Does the Chance Direct Enzymatic Enantioselectivity?', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 867 — 869

**To link to this Article:** DOI: 10.1080/15257779908041585

**URL:** <http://dx.doi.org/10.1080/15257779908041585>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**INTERACTION OF  $\beta$ -L-ADENOSINE-5'-TRIPHOSPHATE (L-ATP) WITH HUMAN DEOXYCYTIDINE KINASE, HUMAN DNA PRIMASE AND T4 DNA LIGASE: DOES THE CHANCE DIRECT ENZYMATIC ENANTIOSELECTIVITY?**

A. Verri<sup>1</sup>, A. Montecucco<sup>1</sup>, G. Gosselin<sup>2</sup>, V. Boudou<sup>2</sup>, S. Spadari<sup>1</sup>, J.-L. Imbach<sup>2</sup> and F. Focher<sup>1\*</sup>


<sup>1</sup>IGBE, CNR, Via Abbiategrasso 207, I-27100 PAVIA, Italy.

<sup>2</sup>Laboratoire de Chimie Bioorganique UMR CNRS-USTL 5625, Université Montpellier II, 34095 Montpellier cedex 5, France.

**ABSTRACT:** We demonstrate that L-ATP: 1) as well as its natural D-enantiomer, acts as a phosphate donor in the reaction catalysed by human deoxycytidine kinase; 2) inhibits human DNA-primase and the ATP-dependent T4 DNA ligase. Thus, the lack of enantioselectivity of the enzymes is more frequent than it was believed a few years ago and we suggest that it would depend on chance more than on an evolutionary strategy.

Enzymes are thought to be able to bind effectively to only one enantiomer of a chiral substrate. However, some exceptions to this rule have recently been found among enzymes involved in the synthesis and polymerisation of deoxyribonucleotides<sup>1</sup>. In fact, we have demonstrated that herpes virus thymidine kinase (TK) human mitochondrial TK, cellular deoxycytidine kinase (dCK), some cellular and viral DNA polymerases (such as DNA polymerase  $\alpha$ , HIV-1 reverse transcriptase, etc) are able to recognise and metabolise L-nucleosides or L-nucleotides<sup>2-4</sup>. The lack of enantioselectivity of HSV TK and human dCK represents the molecular basis for the development of L-thymidine and L-deoxycytidine analogues as antiviral and anticancer drugs<sup>1</sup>.

In the present work we studied the enantioselectivity for ATP of some enzymes involved in DNA synthesis such as human dCK, human DNA primase, *E. coli* RNA polymerase and T4 DNA ligase.



**FIG. 1.** Effect of L-ATP on human dCK and human DNA primase activity. Panel A: kinetics of human dCK activity in presence of 1 mM D-ATP (B), 1 mM L-ATP (E) and in absence of ATP (J). Panel B: Lineweaver-Burk plot of the effect of L-ATP on the activity of human DNA primase. L-ATP: (G) 0  $\mu\text{M}$ ; (A) 100  $\mu\text{M}$ ; (E) 200  $\mu\text{M}$  and (C) 400  $\mu\text{M}$ .

Human dCK lacks enantioselectivity not only for the nucleoside substrate, but also for the phosphate donor. In fact, we found that both D-ATP and L-ATP are indifferently used

by human dCK to phosphorylate dCyd (**FIG. 1A**), whereas the herpes virus TKs, whose gene sequences suggest a common origin with human dCK, are unable to utilise L-ATP as a phosphate donor (data not shown). Human cytoplasmic TK is strictly enantioselective for both thymidine<sup>2</sup> and ATP (data not shown). L-ATP competitively inhibited human DNA primase activity with a  $K_i$  value of 80  $\mu\text{M}$  (**FIG. 1B**). This indicates that the active site of the enzyme is non-enantioselective being able to recognize both enantiomers of ATP with comparable efficiency. On the contrary, *E. coli* RNA polymerase, which, like DNA primase, synthesises RNA chains utilizing ATP as a substrate, is strictly enantioselective and does not recognize L-ATP at all. L-ATP inhibits the adenylation reaction of T4 DNA ligase with an estimated  $\text{IC}_{50}$  value of 4.2  $\mu\text{M}$ . We have previously demonstrated that T4 DNA ligase can perform two different kind of complex with DNA, depending on its adenylation state: a stable complex in the absence of ATP and a transient complex in the presence of ATP. Only in the absence of ATP the DNA/enzyme complex is sufficiently stable to allow the DNA retardation in a electromobility-shift assay (EMSA). Therefore we challenged L-ATP in comparison with

D-ATP in this assay and we found that no band retardation occurred in the presence of L-ATP, indicating that L-ATP was able to modulate the binding of DNA ligase to DNA in the same manner of D-ATP (data not shown). This result suggests that L-ATP can be used for the adenylation step of the enzyme reaction. Although able to adenylate the enzyme, L-ATP is not effective as a cofactor in the joining reaction of poly-d(AT). However, it competitively inhibits the D-ATP dependent joining reaction with an estimated  $K_i$  value of 24  $\mu$ M.

Since the emergence of an enzymatic behavior depends on natural selection, we think that enantioselectivity could have been very important at the origin of life when different choices were possible. But now, in a world made up only by D-nucleosides and L-aminoacids, the enantioselectivity of the enzymes may be purely a side effect and not a vital choice, thus depending more on chance than on evolutionary strategies. From a structural point of view, our findings on substrate/enzyme interactions could be interpreted by an extension of the Koshland's "hand-in-glove" metaphor. In fact, rather than by the "hand-in-glove", it could be better represented by a "hand-in-mitten" metaphor<sup>5</sup>, in which the thumb would be the aminoacid pocket interacting with the adenine moiety of ATP, while the rest of the mitten would fit the sugar-triphosphate moiety as well as it would fit the right or the left hand.

#### Acknowledgments

This work was supported by grants from PF Biotecnologie, TMR-ERBMRXCT 970125, AIRC and "Agence Nationale de Reserche sur le SIDA (ANRS, France). A. V. was supported by a fellowship provided by "Fondazione A. Buzzati-Traverso.

#### REFERENCES

- 1 Spadari, S.; Maga, G.; Verri, A.; Focher, F. *Exp. Opin. Invest. Drugs*, **1998**, *7*, 1285-1300.
- 2 Spadari, S.; Maga, G.; Focher, F.; Ciarrocchi, G.; Manservigi, R.; Arcamone, F.; Capobianco, M.; Carcuro, A.; Colonna, F.; Iotti, S.; Garbesi, A. *J. Med. Chem.*, **1992**, *35*, 4214-4220.
- 3 Verri, A.; Focher, F.; Priori, G.; Gosselin, G.; Imbach, J.-L.; Capobianco, M.; Garbesi, A.; Spadari, S. *Mol. Pharmacol.*, **1997**, *51*, 132-138.
- 4 Focher, F.; Maga, G.; Bendiscioli, A.; Capobianco, M.; Colonna, F.; Garbesi, A.; Spadari, S. *Nucl. Acids Res.*, **1995**, *23*, 2840-2847.
- 5 Garbesi, A.; Hamy, F.; Maffini, M.; Albrecht, G.; Klimkait, T. *Nucl. Acids Res.*, **1998**, *26*, 2886-2890.